Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Endocyte
About
Endocyte is a biopharmaceutical company that develops receptor-targeted therapeutics to treat cancer and inflammatory diseases.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $15M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1996
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 19, 2010 | Series C | $26M | 1 | — | — | Detail |
| Mar 26, 2007 | Series C | $15M | 1 | — | — | Detail |
| Nov 13, 2006 | Series Unknown | $30M | 1 | — | — | Detail |
| May 22, 2003 | Series C | $12.64M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
CID Equity Partners
|
— | Series Unknown |
